Technologies available for licensing, investment, joint ventures and R&D contracts in Ukraine, Azerbaijan, Georgia, Moldova, Uzbekistan

Frontpage Slideshow (version 2.0.0) - Copyright © 2006-2008 by JoomlaWorks

Google Translate

Patenting Information

Tag Cloud



Free counters!

Home Biotechnologies Adjuvant For Improvement Of Cancer Vaccines

Adjuvant For Improvement Of Cancer Vaccines

Description

Cancer vaccines usually consist of non-immunogenic tumor antigens and so have low immunotherapeutic efficacy. Therefore, development of potent immunoadjuvants is effective strategy for successful application of cancer vaccines. New potent natural origin adjuvant has been developed in the Tumor Enzymology Department of R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine. It is bacterial DNA containing unmethylated CpG motifs isolated from Bacillus subtilis culture medium. Adjuvant consists of short fragments of extracellular DNA diluted in sterile physiological saline. Administration of small doses adjuvant allows to im-prove significantly an immunization by low-immunogenic antigens and stimulates a rapid generation of potent immune response. The immune response induced by bacterial CpG DNA-containing adjuvant is based on a natural reaction, therefore, unlike many oil-based adjuvants, it does not induce symptoms of toxicity in immunized organism.

Innovative Aspect and Main Advantages

The main competitive advantages of the adjuvant are:

  • natural origin adjuvant;
  • easy technology of preparation;
  • adjuvant contains of several different types of immunostimulatory CpG-sequences;
  • adjuvant can be used with most types of an-tigen, including peptides, soluble proteins, virus-like particles, whole cell preparations, and polysaccharide conjugates;
  • less antigen required comparatively to the conventional methods;
  • non-toxic adjuvant has no adverse side ef-fects.

Areas of Application

Adjuvant can be used for:

  • augmentation of efficacy of cancer vaccines;
  • adoptive cancer immunotherapy;
  • enhance of cellular and humoral immune re-sponses;
  • IFN α/γ induction;
  • comparative preclinical investigations of can-cer immunotherapeutic drugs.


Fig. 1 Efficacy of immunotherapeutic application of CpG DNA-containing
adjuvant in vaccinotherapy of mice with transplanted sarcoma 37.

Stage of Development

New technology for CpG DNA adjuvant preparing has been proposed, method for quality control and technology of its application for cancer immunotherapy has been elaborated. Clinical trials are under way.

Contact Details

R.E.Kavetsky Institute of experimental pathology, oncology and radiobiology of the National Academy of Sciences of Ukraine
Shlyakhovenko V.O.
45, Vasylkivska St., 03022, Kyiv, Ukraine
Tel: (38 044) 259 91 95
Fax: (38 044) 258 16 56
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Website: www.onconet.kiev.ua

Add comment


Security code
Refresh

For additional technologies go to: http://www.stcu.int